The novel role of the kidney in diabetes management: Sodium-glucose co-transporter 2 inhibitors

Arthur L Swislocki, Ishwarlal Jialal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The global epidemic of diabetes continues to progress, despite efforts of public health agencies and health care systems to identify and treat impacted patients. Although lifestyle is the cornerstone of treatment, there is an array of pharmacologic agents now available, many in classes that did not exist a few years ago. In addition to insulin and its secretogogues, such as sulfonylureas, there are agents that improve insulin action, reduce gastric emptying, reduce glucagon concentrations, and sympathetic nervous system activity. A novel class recently entering the fray includes drugs that interfere with renal glucose reabsorption. These drugs, collectively called sodium-glucose co-transporter 2 (SGLT2) inhibitors, are available both as single agents and in various combinations. They work by promoting glycosuria and may have benefits that extend beyond lowering glycemia, such as weight loss and blood pressure reduction. This review focuses on several of these new agents and considers their efficacy and potential side effects. We address drugs approved for use in the United States at the time of this writing (March, 2015), but do not address recently approved combination agents.

Original languageEnglish (US)
Pages (from-to)287-291
Number of pages5
JournalMetabolic Syndrome and Related Disorders
Volume13
Issue number7
DOIs
StatePublished - Sep 1 2015

Fingerprint

Sodium-Glucose Transporter 2
Symporters
Kidney
Pharmaceutical Preparations
Insulin
Glycosuria
Gastric Emptying
Sympathetic Nervous System
Glucagon
Life Style
Weight Loss
Public Health
Blood Pressure
Delivery of Health Care
Glucose

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The novel role of the kidney in diabetes management : Sodium-glucose co-transporter 2 inhibitors. / Swislocki, Arthur L; Jialal, Ishwarlal.

In: Metabolic Syndrome and Related Disorders, Vol. 13, No. 7, 01.09.2015, p. 287-291.

Research output: Contribution to journalArticle

@article{ff4467eb5be346579cfaed39a5cddff6,
title = "The novel role of the kidney in diabetes management: Sodium-glucose co-transporter 2 inhibitors",
abstract = "The global epidemic of diabetes continues to progress, despite efforts of public health agencies and health care systems to identify and treat impacted patients. Although lifestyle is the cornerstone of treatment, there is an array of pharmacologic agents now available, many in classes that did not exist a few years ago. In addition to insulin and its secretogogues, such as sulfonylureas, there are agents that improve insulin action, reduce gastric emptying, reduce glucagon concentrations, and sympathetic nervous system activity. A novel class recently entering the fray includes drugs that interfere with renal glucose reabsorption. These drugs, collectively called sodium-glucose co-transporter 2 (SGLT2) inhibitors, are available both as single agents and in various combinations. They work by promoting glycosuria and may have benefits that extend beyond lowering glycemia, such as weight loss and blood pressure reduction. This review focuses on several of these new agents and considers their efficacy and potential side effects. We address drugs approved for use in the United States at the time of this writing (March, 2015), but do not address recently approved combination agents.",
author = "Swislocki, {Arthur L} and Ishwarlal Jialal",
year = "2015",
month = "9",
day = "1",
doi = "10.1089/met.2015.1504",
language = "English (US)",
volume = "13",
pages = "287--291",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - The novel role of the kidney in diabetes management

T2 - Sodium-glucose co-transporter 2 inhibitors

AU - Swislocki, Arthur L

AU - Jialal, Ishwarlal

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The global epidemic of diabetes continues to progress, despite efforts of public health agencies and health care systems to identify and treat impacted patients. Although lifestyle is the cornerstone of treatment, there is an array of pharmacologic agents now available, many in classes that did not exist a few years ago. In addition to insulin and its secretogogues, such as sulfonylureas, there are agents that improve insulin action, reduce gastric emptying, reduce glucagon concentrations, and sympathetic nervous system activity. A novel class recently entering the fray includes drugs that interfere with renal glucose reabsorption. These drugs, collectively called sodium-glucose co-transporter 2 (SGLT2) inhibitors, are available both as single agents and in various combinations. They work by promoting glycosuria and may have benefits that extend beyond lowering glycemia, such as weight loss and blood pressure reduction. This review focuses on several of these new agents and considers their efficacy and potential side effects. We address drugs approved for use in the United States at the time of this writing (March, 2015), but do not address recently approved combination agents.

AB - The global epidemic of diabetes continues to progress, despite efforts of public health agencies and health care systems to identify and treat impacted patients. Although lifestyle is the cornerstone of treatment, there is an array of pharmacologic agents now available, many in classes that did not exist a few years ago. In addition to insulin and its secretogogues, such as sulfonylureas, there are agents that improve insulin action, reduce gastric emptying, reduce glucagon concentrations, and sympathetic nervous system activity. A novel class recently entering the fray includes drugs that interfere with renal glucose reabsorption. These drugs, collectively called sodium-glucose co-transporter 2 (SGLT2) inhibitors, are available both as single agents and in various combinations. They work by promoting glycosuria and may have benefits that extend beyond lowering glycemia, such as weight loss and blood pressure reduction. This review focuses on several of these new agents and considers their efficacy and potential side effects. We address drugs approved for use in the United States at the time of this writing (March, 2015), but do not address recently approved combination agents.

UR - http://www.scopus.com/inward/record.url?scp=84952059199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952059199&partnerID=8YFLogxK

U2 - 10.1089/met.2015.1504

DO - 10.1089/met.2015.1504

M3 - Article

C2 - 25893855

AN - SCOPUS:84952059199

VL - 13

SP - 287

EP - 291

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 7

ER -